SCHEMBL27433787

SCHEMBL27433787

COC(=O)c1c(OC)c(Cl)cc2c1OCCN2/C=C/c1cc(F)cc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.37
MAPT P10636 5/20 0.33
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 2/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 2/20 0.33
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.33
ALOX15 P16050 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.32
CPT2 P23786 4/20 0.32
CPT1A P50416 4/20 0.32
CPT1B Q92523 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32
NFKB1 P19838 1/20 0.32
RAB9A P51151 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30954110 1.00 ENPP2 (0.37) ENPP2MAPTKDM4EHSD17B10LMNA
SCHEMBL30954128 0.91 CPT1A (0.34) MAPTKDM4EHSD17B10LMNATSHR
SCHEMBL27433819 0.82
SCHEMBL27434669 0.76 MAPT (0.39) ENPP2MAPTKDM4EHSD17B10KMT2A
SCHEMBL27435327 0.74 DRD2 (0.40) KDM4EHSD17B10LMNAKMT2ATP53
SCHEMBL27434847 0.74 TAS1R3 (0.36) ENPP2MAPTKDM4EHSD17B10KMT2A
SCHEMBL27432939 0.73 MAPT (0.38) MAPTKDM4EHSD17B10TSHRALDH1A1
SCHEMBL27435492 0.73 CPT2 (0.32) ENPP2MAPTKDM4EHSD17B10LMNA
SCHEMBL27435244 0.71 TP53 (0.43) MAPTKDM4ETSHRALDH1A1KMT2A
SCHEMBL27435508 0.70 DRD3 (0.41) MAPTLMNATSHRALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed